:max_bytes(150000):strip_icc():format(jpeg)/Health-GettyImages-2177502752-47a7385bbc284648b51a74f3f9d610ab.jpg?w=350&resize=350,250&ssl=1 "Symptoms, Risk Factors, Complications, Treatment")
:max_bytes(150000):strip_icc():format(jpeg)/Health-GettyImages-2177502752-47a7385bbc284648b51a74f3f9d610ab.jpg?w=120&resize=120,86&ssl=1 "Symptoms, Risk Factors, Complications, Treatment")
[Articles] Long-term efficacy and safety of upadacitinib in patients with moderately to severely active ulcerative colitis: an interim analysis of the phase 3 U-ACTIVATE long-term extension study
This interim analysis supports the positive long-term risk–benefit profile for upadacitinib 15 mg and 30 mg among patients with moderately ...
